Calcium Pyrophosphate Crystal Deposition Disease Pseudogout

Slide 1 · Calcium Pyrophosphate Crystal

Deposition Disease

Pseudogout

Crystal biology • morphology • clinicopathologic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning sequence

Interpret a crystal-induced joint disorder from mechanism to manifestations.

Define

CPP deposits in and around joints

Explain

Cartilage proteoglycans and crystal formation

Recognize

Morphology and polarized optics

Integrate

Clinical, imaging and therapeutic implications

Mechanistic interpretation

Central question: How can cartilage mineralization lead to either silent chondrocalcinosis or inflammatory and destructive arthropathy?

Slide 3 · What defines CPPD?

Calcium pyrophosphate crystals accumulate within and around joints.

The condition may be asymptomatic, acutely inflammatory, or chronically symptomatic.

Cartilage is the major site of initial crystal formation.

Clinical manifestations depend on both crystal deposition and tissue response.

Deposited crystals are not synonymous with an acute attack.

Slide 4 · Three related terms

Distinguish the material, the disease expression, and the radiographic sign.

CPP crystals

The deposited calcium pyrophosphate mineral material is the defining pathological substrate.

CPPD / pseudogout

The textbook uses pseudogout as a synonym for CPPD, which spans variable clinical phenotypes.

Chondrocalcinosis

Radiographically evident calcification of hyaline cartilage or fibrocartilage; It may be clinically silent.

Slide 5 · Two crystal-induced arthropathies

The precipitating mineral distinguishes the disorders.

Feature

CPPD

Gout

Crystal type

Calcium pyrophosphate

Monosodium urate

Principal initiating location

Hyaline/fibrocartilage

Urate precipitation in joint tissues

Shared inflammatory link

Inflammasome → IL-1

Inflammasome → IL-1

Morphologic clue

Rhomboid crystals

Needle-shaped crystals

Feature

CPPD

Gout

Slide 6 · Age is a major contextual clue

CPPD becomes increasingly prevalent with advancing age.

Typical presentation after 50 years of age.

It reports involvement in up to 60% of people aged 85 years or older.

Older age supports the differential diagnosis but does not specify symptom severity.

A high prevalence of deposits does not mean all individuals develop arthritis.

Slide 7 · The spectrum is wider than acute arthritis

A single crystal disease can have markedly different clinical expressions.

Silent deposition

Crystals may persist without clinically evident inflammation or pain.

Acute attacks

Sudden painful inflammation in one or a few joints, sometimes prolonged.

Chronic arthropathy

Persistent joint symptoms, acute flares, and potential structural damage.

Slide 8 · Etiologic classification

Robbins groups CPPD into three broad categories.

Sporadic (idiopathic)

CPPD without a defined familial or predisposing associated disorder.

Hereditary

Some forms are linked to inherited variants affecting pyrophosphate or bone-related biology.

Secondary

CPPD arising with pre-existing joint damage or specific metabolic and endocrine conditions.

Slide 9 · Sporadic CPPD

The idiopathic category lacks a recognized secondary context.

Age-associated CPP deposition is compatible with sporadic disease.

Absence of a hereditary syndrome does not exclude CPPD.

Classification concerns background cause, not the severity or duration of an acute episode.

Etiologic type and clinical phenotype describe different dimensions.

Slide 10 · Secondary CPPD: Associated contexts

These are reported associations—not universal prerequisites.

Pre-existing damage

Previous structural injury or joint damage can coexist with secondary CPPD.

Endocrine disorders

Hyperparathyroidism and hypothyroidism are cited associations.

Metabolic and other disorders

Hemochromatosis, hypomagnesemia, ochronosis, and diabetes are listed.

Slide 11 · Previous joint damage and deposition

Previous joint damage as a secondary setting.

Joint injury

Altered tissue environment

Cartilage changes

Matrix architecture can be disturbed

Crystal formation

Deposits may develop

CPP arthropathy

Subsequent structural or inflammatory consequences

Mechanistic interpretation

This is a conceptual sequence organizing the association; The source does not establish that every damaged joint will develop CPPD.

Slide 12 · Secondary associations to recognize

Do not infer causation from the association alone.

01

Hyperparathyroidism and hypothyroidism: Endocrine contexts.

02

Hemochromatosis and hypomagnesemia: Metabolic contexts.

03

Ochronosis and diabetes: Additional associated disorders.

All listed settings come from the Robbins CPPD section.

Slide 13 · ANKH links genetics to pyrophosphate handling

ANKH encodes a transporter of inorganic pyrophosphate.

Mutations in ANKH have been linked to some forms of CPPD.

A plausible disease connection involves local pyrophosphate availability.

The text does not assign ANKH abnormalities to every sporadic or secondary case.

Reported linkage ≠ universal genetic cause.

Slide 14 · OPG provides a second genetic link

The source also associates some CPPD forms with OPG.

OPG encodes osteoprotegerin, a decoy receptor for RANKL.

The OPG–RANKL relationship belongs to skeletal regulatory biology.

A genetic association, not a universal disease-causing mechanism.

Keep genetic association distinct from the established crystal–inflammation cascade.

Slide 15 · What is established—and what is proposed?

Separate a central morphological observation from mechanistic models.

Observation

Interpretation

CPP crystals form in cartilage

Core morphological site in the source

Proteoglycan degradation can permit deposits

Proposed permissive mechanism based on studies

ANKH / OPG linked to some cases

Genetic association, not all-case explanation

CPP crystals provoke IL-1-linked inflammation

Established mechanistic pathway described in Robbins

Observation

Interpretation

Slide 16 · Cartilage is the primary crystal niche

CPP crystals form in hyaline cartilage and fibrocartilage.

Articular hyaline cartilage

Joint space

Articular hyaline cartilage

Fibrocartilage

Schematic

Tissue-level starting point

Deposits surround chondrocytes.

Inflammation may be absent initially.

Articular cartilage contains a matrix that normally resists mineralization.

Slide 17 · Proteoglycans restrain mineralization

Articular cartilage proteoglycans normally oppose mineral precipitation.

Intact matrix

Proteoglycan-rich cartilage

Mineralization restraint

Inhibition of crystal growth

Joint homeostasis

Cartilage remains functional

Mechanistic interpretation

The proposed relationship helps explain why loss of matrix integrity may make the cartilage environment more permissive to CPP crystallization.

Slide 18 · Proteoglycan breakdown enables crystals

A model rather than a complete universal mechanism.

Matrix change

Proteoglycan degradation

Loss of inhibition

Mineralization becomes permissive

CPP crystallization

Deposits near chondrocytes

Tissue consequences

Structural and inflammatory disease

Mechanistic interpretation

A plausible sequence connects a cartilage alteration to deposition; The initiating events may differ among idiopathic, hereditary, and secondary cases.

Slide 19 · Crystals accumulate around chondrocytes

The source places early CPP crystallization in cartilage matrix.

Articular hyaline cartilage

Joint space

Articular hyaline cartilage

Fibrocartilage

Schematic

Pericellular deposits

Cartilage is the initial site.

Crystals arise around chondrocytes.

Increasing material can later reach the joint space.

Slide 20 · CPP and urate begin in different substrates

The site of initial crystallization has clinicopathologic implications.

CPP deposition

Urate deposition

Formation is described within hyaline and fibrocartilage.

Urate crystals precipitate within tissues and joint compartments.

Deposits can rupture or seed the joint cavity.

Urate crystals drive acute gouty synovial inflammation.

Both can activate the inflammasome.

Both have an IL-1-mediated leukocyte response.

CPP deposition

Urate deposition

Slide 21 · How CPP crystals cause an acute flare

The inflammatory route is explicitly described.

CPP crystals become accessible to inflammatory cells

Inflammasome activation occurs

IL-1 is released

Leukocytes are recruited

Acute joint inflammation develops

The schematic represents a mechanism, not a patient-specific time course.

Slide 22 · IL-1 connects crystals to leukocyte influx

The inflammasome–IL-1 axis explains inflammatory attacks.

Crystal deposition alone is insufficient to predict active symptoms.

Activation of the inflammasome stimulates IL-1 release.

IL-1 mediates recruitment of leukocytes to the affected joint.

A molecular mechanism explains why noninfectious crystals produce inflammatory symptoms.

Slide 23 · Two routes from crystals to joint damage

Inflammation and matrix disruption may coexist or occur separately.

Inflammatory route

CPP crystals activate the inflammasome, producing IL-1-mediated leukocyte recruitment.

Structural route

Crystals deposited in cartilage can directly disturb matrix structure and function.

Clinical endpoint

Symptoms and damage vary according to the balance of crystal burden and tissue response.

Slide 24 · Why deposits may be clinically silent

A joint may contain CPP crystals without overt arthritis.

CPPD is frequently asymptomatic.

Crystal accumulation is not equivalent to sustained leukocyte recruitment.

Matrix disruption may occur even when an active inflammatory episode is absent.

Disease burden must be interpreted with both morphology and clinical features.

Slide 25 · Progression from matrix to joint cavity

A physical pathway for dissemination of deposits.

Initiation

CPP crystals develop in cartilage

Growth

Deposits enlarge within matrix

Rupture

Aggregates reach tissue surfaces

Seeding

Joint space receives crystal material

Mechanistic interpretation

Crystals in the joint cavity can participate in acute inflammatory episodes.

Slide 26 · Hyaline cartilage involvement

Articular hyaline cartilage is a prominent site of formation.

Articular hyaline cartilage

Joint space

Articular hyaline cartilage

Fibrocartilage

Schematic

Morphological distribution

Crystals can develop in cartilage.

H&E may reveal blue-purple aggregates.

CPP deposits may subsequently extend toward the joint space.

Slide 27 · Fibrocartilage involvement

CPPD is also documented in fibrocartilaginous structures.

Articular hyaline cartilage

Joint space

Articular hyaline cartilage

Fibrocartilage

Schematic

Relevant locations

Menisci are described sites.

Intervertebral disks are also included.

Such deposits are part of the distribution of CPP mineralization.

Slide 28 · Crystal release can seed the joint

Deposits grow within matrix before material reaches the joint space.

Articular hyaline cartilage

Joint space

Articular hyaline cartilage

Fibrocartilage

Schematic

Link to the clinical flare

Enlarging deposits may rupture.

Released CPP can enter a joint.

The inflammatory response depends on activation of the crystal-sensing pathway.

Slide 29 · Gross appearance of CPP deposits

Larger crystal aggregates form chalky, white, friable material.

Deposits can accumulate within articular cartilage and fibrocartilage.

The white friable appearance reflects concentrated crystalline material.

Gross deposits should not automatically be equated with symptomatic synovitis.

Gross morphology establishes mineral deposition, not its clinical activity.

Slide 30 · CPP deposits on hematoxylin–eosin

Oval, blue-purple crystalline aggregates.

Aggregates are demonstrable in H&E-stained tissue sections.

Distribution in cartilage helps connect morphology with disease pathogenesis.

Fine individual crystal geometry is assessed with polarization.

Schematic representation only; No source photomicrograph was available.

Slide 31 · Individual CPP crystals: Size and shape

The source specifies rhomboid crystals measuring 0.5–5 μm.

Characteristic crystal geometry

0.5–5 μm

Rhomboid crystal shape

Individual CPP crystals are small and rhomboid rather than long, slender needles.

Schematic: Not a photomicrograph

Slide 32 · Positive birefringence in CPPD

For parallel alignment, CPP crystals appear blue with a compensator.

Compensated polarized light

Axis of polarizer →

Positive birefringence

CPP crystals take a blue tinge when parallel to the polarizer axis.

Schematic: Not a photomicrograph

Slide 33 · CPP crystals versus urate crystals

Crystal geometry and compensated optical behavior differ.

Parameter

CPP

Monosodium urate

Typical shape

Rhomboid

Slender needle

Birefringence

Positive

Negative

Parallel to polarizer axis

Blue tint

Yellow tint

Primary textbook example

CPPD / pseudogout

Gout

Parameter

CPP

Monosodium urate

Slide 34 · Inflammation is generally milder than in gout

CPPD still produces clinically important acute and chronic disease.

The source explicitly states that inflammation is usually milder than in gout.

The relative degree of inflammation does not exclude marked joint pain.

Morphologic evidence of crystals remains separate from pain severity.

“Usually milder” is a comparative tendency, not an absolute diagnostic rule.

Slide 35 · CPPD has three broad clinical expressions

Pattern recognition begins by classifying the presentation.

Asymptomatic

CPP deposits can be present without joint symptoms.

Acute arthritis

Sudden pain in one or a few joints; Episodes may be prolonged.

Chronic arthritis

Persistent pain with superimposed acute flares, sometimes mimicking OA or RA.

Slide 36 · Acute CPP arthritis often affects few joints

An attack may begin abruptly and involve one or several joints.

Sudden pain is a characteristic symptomatic presentation.

Monoarticular and oligoarticular patterns are both described.

An acute presentation may still occur against a chronic deposition background.

The acute syndrome is a clinical response to crystals, not the entirety of CPPD.

Slide 37 · CPPD flares may be prolonged

The textbook contrasts attack duration with that of gout.

Feature

CPPD

Gout

Acute joint pain

Can persist for weeks to months

Typical untreated attack lasts hours to weeks

Clinical course

Can also become chronic with flares

Intercritical asymptomatic phases described

Interpretation

Prolonged symptoms remain compatible

Time course alone is not diagnostic

Feature

CPPD

Gout

Slide 38 · Distribution of joint involvement

Frequency order supplied in the CPPD source.

01

Knees are affected most commonly.

02

Wrists are next among commonly affected joints.

03

Elbows, shoulders, and ankles are also frequent sites.

These are qualitative site frequencies, not percentages.

Slide 39 · The knee is a useful clinical anchor

Joint distribution is one element of the differential.

In the source, the knee is the leading site of symptomatic CPPD.

Other large and medium joints can also be involved.

A compatible site does not replace crystal or radiographic evidence.

An older patient with acute knee pain has a compatible CPPD pattern.

Slide 40 · Chronic CPPD can resemble osteoarthritis

Persistent symptoms may obscure the contribution of crystal disease.

The chronic form produces persistent joint pain.

Superimposed acute flares distinguish an episodic inflammatory component.

CPPD can be clinically confused with osteoarthritis.

Underlying degenerative and crystal-related processes may coexist.

Slide 41 · Chronic CPPD can resemble rheumatoid arthritis

Chronic inflammatory complaints do not uniquely identify RA.

CPPD may produce persistent pain with episodes of acute synovitis.

The clinical syndrome can resemble rheumatoid arthritis.

The crystal substrate and cartilage distribution provide pathologic discrimination.

The comparator is a clinical mimic, not a shared crystal etiology.

Slide 42 · Chondrocalcinosis is a radiographic finding

It denotes visible calcification in cartilage.

The affected tissue can be hyaline cartilage or fibrocartilage.

CPP crystals are a typical cause of chondrocalcinosis.

The finding is not itself proof of symptomatic CPPD.

Image manifestation and symptomatic syndrome are separate observations.

Slide 43 · Calcification does not equal inflammation

Clinical interpretation must account for three distinct domains.

Crystal presence

Cartilage deposits can exist in clinically silent individuals.

Radiographic visibility

Chondrocalcinosis describes demonstrable cartilage calcification.

Inflammatory symptoms

Painful attacks reflect a biological response to crystal material.

Slide 44 · Structural injury can accrue without a flare

Crystal deposits may directly disrupt cartilage matrix.

Robbins allows matrix damage independent of active inflammation.

Recurrent attacks add another potential pathway to joint dysfunction.

Approximately 50% of affected individuals are described as experiencing significant joint damage.

The quoted estimate concerns joint damage, not a treatment response rate.

Slide 45 · Clinicopathologic interpretation framework

Start with the tissue process, then decide which phenotype is present.

Context

Age and associated disorders

Distribution

Knee or other affected joint

Evidence

Crystals / cartilage calcification

Expression

Silent, acute or chronic disease

Mechanistic interpretation

Use the constellation rather than relying on any single fact such as age, radiographic calcification, or acute pain.

Slide 46 · Case 1: Sudden knee arthritis

Clinical vignette

A 76-year-old patient has sudden painful swelling of one knee. Imaging shows cartilage calcification. Microscopy identifies rhomboid crystals with positive birefringence.

Reasoning task

Which integrated explanation fits best?

A. CPPD with acute arthritis

B. Urate gout only

C. Calcification always silent

Hypothetical case for teaching

Slide 47 · Case 1: Reasoning through the findings

The combination supports symptomatic CPPD.

Older age and knee involvement fit the textbook epidemiology.

Cartilage calcification supports the site of CPP deposition.

Rhomboid, positively birefringent crystals identify the CPP substrate.

The vignette is hypothetical; The pattern is the teaching point.

Slide 48 · Case 2: Chronic pain with flares

Clinical vignette

A 68-year-old patient has persistent wrist and knee pain interrupted by acute painful exacerbations. The working clinical differential includes osteoarthritis and rheumatoid arthritis.

Reasoning task

What disease mechanism deserves consideration?

A. CPP deposits with chronic flares

B. Only septic arthritis

C. Urate nephropathy

Hypothetical case for teaching

Slide 49 · Case 2: Chronic phenotype reasoning

CPPD can generate persistent symptoms with superimposed attacks.

The source explicitly describes an OA-like or RA-like chronic presentation.

Wrist and knee involvement is consistent with the distribution.

CPPD biology can combine structural matrix disturbance and crystal-mediated inflammation.

Neither chronic pain nor an acute flare alone defines the crystal species.

Slide 50 · Therapy targets inflammatory consequences

Symptomatic anti-inflammatory approaches.

NSAIDs

Listed treatment option for symptomatic CPPD.

Colchicine / corticosteroids

Additional anti-inflammatory therapies in the source.

IL-1 inhibitors

Target the cytokine pathway described in CPP-mediated inflammation.

Slide 51 · There is no established crystal-preventing therapy

Existing therapy does not prevent or slow crystal formation.

Anti-inflammatory interventions address symptoms and attacks.

Control of inflammation does not imply elimination of the mineral deposits.

Structural damage may remain clinically important despite flare treatment.

Distinguish symptom control from modifying crystal deposition.

Slide 52 · High-yield CPPD–gout comparison

Differences at the substrate, morphology, and clinical levels.

Domain

CPPD

Gout

Crystal

Calcium pyrophosphate

Monosodium urate

Crystal morphology

Rhomboid; positive

Needle; negative

Typical site

Knee is most common

First MTP in many first attacks

In tissue

Cartilage nucleation

Tophi and urate deposits

Course

Often silent or chronic; flares

Acute + intercritical + chronic stages

Domain

CPPD

Gout

Slide 53 · Retrieval questions

Use morphology to explain clinical observations.

01

Why may crystal-containing cartilage remain asymptomatic?

02

What links proteoglycan degradation with CPP crystallization?

03

How do rhomboid geometry and positive birefringence distinguish CPP from urate?

04

Why is chondrocalcinosis not equivalent to symptomatic CPPD?

Slide 54 · A unifying model of CPPD

Every phenotype begins with crystal deposition; Effects depend on tissue response.

Susceptible cartilage

Matrix change ± associated context

CPP formation

Cartilage and fibrocartilage

Two responses

IL-1 inflammation / matrix disruption

Clinical spectrum

Silent, acute, chronic and damaging

Mechanistic interpretation

Central teaching principle: Crystal type, deposition compartment, and host inflammatory response must be interpreted together.

Slide 55 · Core references and figure provenance

Primary textbook

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th ed. 2026. Chapter 26, pp. 1094–1097 (CPPD section and adjacent gout comparison).

Figure and teaching-material integrity

All diagrams are original editable teaching schematics, not photomicrographs, radiographs, patient images or reproductions of textbook figures. Case scenarios are constructed examples.